Lindbrook Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Lindbrook Capital’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-37	Closed	-$1K	–	2723
2022 Q1	$1K	Buy	+37	New	+$1K	﹤0.01%	2336

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lindbrook Capital's RIGL Position: Q2 2022 in Review

Lindbrook Capital sold out of Rigel Pharmaceuticals (RIGL) in Q2 2022, closing a stake of 37 shares — an estimated $1K sold.

Lindbrook Capital first reported a position in RIGL in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2022.

Lindbrook Capital reported no remaining Rigel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Lindbrook Capital sold 37 Rigel Pharmaceuticals shares in Q2 2022, an estimated $1K.
Lindbrook Capital first reported a position in Rigel Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Lindbrook Capital's Rigel Pharmaceuticals position peaked at $1K in Q1 2022.
135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2022.

Based on Lindbrook Capital's 13F filing for Q2 2022, filed 1 Aug 2022.